Eric Daniels
Corporate Officer/Principal chez KIORA PHARMACEUTICALS, INC.
Fortune : 614 $ au 31/05/2024
Postes actifs de Eric Daniels
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| KIORA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 21/10/2021 | - |
Okogen, Inc.
 Okogen, Inc. Miscellaneous Commercial ServicesCommercial Services Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA. | Directeur/Membre du Conseil | - | - |
| Fondateur | - | - | |
| Bayon Therapeutics, Inc. | Directeur/Membre du Conseil | - | - |
| Fondateur | - | - |
Historique de carrière de Eric Daniels
Anciens postes connus de Eric Daniels
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
OccuRx Pty Ltd
 OccuRx Pty Ltd BiotechnologyHealth Technology OccuRx Pty Ltd provides biopharmaceutical services. It engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. The company was founded by Darren J. Kelly in 2014 and is headquartered in Melbourne, Australia. | Directeur Général | - | - |
Formation de Eric Daniels
| University of California, Berkeley | Undergraduate Degree |
| David Geffen School of Medicine | Doctorate Degree |
| Anderson School of Management | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 7 |
| Australie | 2 |
Opérationnelle
| Director/Board Member | 2 |
| Founder | 2 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Consumer Services | 4 |
| Health Technology | 3 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KIORA PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Okogen, Inc.
Okogen, Inc. Miscellaneous Commercial ServicesCommercial Services Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA. | Commercial Services |
OccuRx Pty Ltd
OccuRx Pty Ltd BiotechnologyHealth Technology OccuRx Pty Ltd provides biopharmaceutical services. It engages in the development of therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis and inflammation. The company was founded by Darren J. Kelly in 2014 and is headquartered in Melbourne, Australia. | Health Technology |
| Bayon Therapeutics, Inc. |
- Bourse
- Insiders
- Eric Daniels
- Expérience
